HOME >> BIOLOGY >> NEWS
Johns Hopkins Scientists Designing Compounds To Fight Malaria

Chemists have developed new compounds that show promise in treating malaria by making the disease-causing parasites self-destruct.

A scientific paper about the compounds will appear in the March 12 issue of the Journal of Medicinal Chemistry, published by the American Chemical Society.

At any given time, about 300 million people suffer from malaria, and as many as 3 million of them, mostly children, will die every year. The most severe form of the infection is caused by tiny parasites called Plasmodium falciparum, which are transmitted by female mosquitos feeding on human blood.

The drug of choice to combat malaria has been chloroquine, a derivative of quinine, which comes from the bark of the Cinchona tree. But the malaria parasites began showing resistance to chloroquine nearly 40 years ago.

Chinese chemists have isolated a new anti-malarial drug from the plant Artemisia annua, which has been used for thousands of years as an herbal remedy for fever. The drug, called artemisinin, has since been proven to be effective against malaria. Chemists have developed derivatives of artemisinin, as well. But artemisinin and its derivatives remain difficult and expensive to produce, and they quickly break down in the human body.

New synthetic compounds being developed at Johns Hopkins have been shown to kill malaria parasites in test tubes and in experiments with mice. Although the synthetic compounds use the same general mechanism as artemisinin, they are not derivatives of the drug; they are a new type of compound that has a much simpler structure. Because they are simpler, they can be made in only three to five chemical steps, compared to 12 or more steps for the artemisinin derivatives.

The research is being conducted by a team of scientists led by Gary H. Posner, Scowe Professor of Chemistry in The Johns Hopkins University School of Arts and Sciences, Theresa A. Sh
'"/>

Contact: Emil Venere
emil@jhu.edu
410-516-7160
Johns Hopkins University
12-Feb-1998


Page: 1 2 3

Related biology news :

1. Yale professor receives Johnson & Johnson Focused Giving award
2. Marian Johnson-Thompson wins 2004 Alice C. Evans Award
3. Conservation International & SC Johnson invest in Ecuadors rainforest to offset climate impacts
4. Johns Hopkins gene hunters pinpoint new cancer gene target
5. OXiGENE announces launch of ophthalmic clinical trial at The Johns Hopkins School of Medicine
6. Johns Hopkins receives $24 million from Donald W. Reynolds Foundation to study sudden cardiac death
7. Johns Hopkins researchers devise methods to evaluate disaster drills
8. Johns Hopkins scientists create forgetful mouse
9. A bed of microneedles: Johns Hopkins scientists gadget measures muscle cell force
10. Wake Forest-Johns Hopkins team discovers prostate cancer gene
11. The next generation of scientists recognized at Johns Hopkins

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Johns Hopkins Scientists Designing Compounds Fight Malaria

(Date:2/24/2015)... DUBLIN , Feb. 24, 2015 Research ... announced the addition of the "Global 2D ... offering. The analysts forecast the ... a CAGR of 32.12% over the period 2014-2019 ... devices in non-traditional sectors is one of the ...
(Date:2/13/2015)... -- ACT Genomics Co., Ltd., a cancer molecular ... genomic information into precision diagnosis and personalized treatments, ... million in the its first private funding round. ... , ACT Genomics has developed comprehensive cancer ... implement next generation sequencing (NGS) and multiplex molecular ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
(Date:2/27/2015)... 2015 A paper published today, " ... " in Science Translational Medicine, demonstrates ... reduce the risk associated with investing in the ... levels of funding for developing so-called "orphan" drugs. ... collaboration between scientists at the National Center for ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine ... and immunotherapy company, today announced that the U.S. ... for Fast Track designation and Phase I clinical ... conjunction with the mutual co-development agreement signed with ... Fast Track designation for the DPX-Survivac. , “We ...
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited ... the DisrupTOR-1 trial of BNC105 in patients with metastatic ... Orlando, Florida . The data will ... the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 ...
(Date:2/27/2015)... 2015 FamilyFarms Group is pleased to ... State Line Farms, received the 2015 Tomorrow’s Top Producer ... the age of 35, who has demonstrated excellence in ... to win the Tomorrow's Top Producer Horizon Award. Every ... Top Producer Award and learning from their experiences. It ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
Cached News: